medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2010, Number 1

<< Back Next >>

Rev Mex Urol 2010; 70 (1)

The role of prolactin in prostate cancer

Mendoza-Romo MÁ, García-Peña E

Language: Spanish
References: 34
Page: 55-60
PDF size: 492.56 Kb.


ABSTRACT

Prostate cancer (CaP) is presently the most frequently diagnosed cancer and represents the second cause of death from the disease in men. The prostate is a hormone-dependent organ and the most important factors in its development, growth and differentiation are androgens and prolactin. This article describes the role of prolactin (PRL) and the androgen receptor (AR) in the development of CaP along with other channels which act separately. The interrelation between PRL and the AR has recently been discovered on a cellular level and potentially will help explain the little-understood hormone-refractory cancer as well as providing new forms of treatment. The authors consider it important to understand these signaling channels and thus were motivated to write this review.


REFERENCES

  1. Mendoza M, Ramírez M, Aguilar J. Características y manejo de la urolitiasis en pacientes que acuden a un hospital general. Med Interna Méx 2001;6(6):292-5.

  2. World Health Organization, Measurement and Health Information, Diciembre 2004. http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates. xls, 28 de Octubre de 2009.

  3. Jemal A, Siegel R, Ward E, Yongping H. Cancer statistics, 2009. Cancer J Clin 2009;59:225-49.

  4. Aus G, Abbou CC, Bolla M, Heindenreich A. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51.

  5. INEGI, Estadísticas a propósito del día mundial contra el cáncer, Edición 2007, pp. 1-3.

  6. Shapiro E, Steiner MS.The embryology and development of the prostate. En: Lepor H (ed.): Prostatic diseases. Philadelphia, WB Saunders Co., 2000:1–16.

  7. Wein AJ, Kavoussi L, Novick A, Partin A, Peters C. Anatomy. Elsevier. Philadelphia, PA, EUA, Campbell-Walsh Urology 9th ed. 2007;(Cap.1).

  8. Zelefsky M, Eastham J, Sartor O, Kantoff P. Cancer of genitourinary systems. En: De Vita, Hellman & Rosenberg’s (eds.): Cancer. Principles & practice of oncology. 8th edition. Philadelphia, Lippincott Williams & Wilkins 2008:1393-1452.

  9. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111(1):58-64.

  10. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr 1988;7:15.

  11. Nelson W, De Marzo A, Isaacs W. Prostate cancer. N Engl J Med 2003;349:366-81.

  12. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.

  13. Grayhack J, Bunce P, Kearns J, Scott W. Influence of the pituitary on prostatic response to androgen in the rat. Bull Johns Hopkins Hosp 1955;96(4):154-63.

  14. Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. A phase II of bromocriptine in patients with androgen-independent prostate cancer. Oncol Rep 1998;5(4):893-6.

  15. Lissoni P, Mandalà M, Giani L, Malugani F, et al. Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer related. Neuro Endocrinol Lett 2000;21(5):405-8.

  16. Shyh-Han Tan, Dagvadorj A, Shen F, Gu L, Liao Z, et al. Transcription factor Stat5 synergizes with androgen receptor prostate cancer cells. Cancer Res 2008;68( 1):236-48.

  17. Owerbach D, Rutter WJ, Cooke NE, Martial JA, Shows TB. The prolactin gene is located on chromosome 6 in humans. Science 1981;212:815–6.

  18. Miller WL, Eberhardt NL. Structure and evolution of the growth hormone gene family. Endocr Rev 1983;4:97–130.

  19. Cooke NE, Coit D, Shine J, Baxter JD, Martial JA. Human prolactin: cDNA structural analysis and evolutionary comparisons. J Biol Chem 1981;256:4007–16.

  20. Bole-Feysot H, Goffin V, Edery M, Binart N, Kelly P. Prolactin (PRL) and its receptor: actions, signals, transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19(3):225-68.

  21. Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev 1991;12:235–51.

  22. Han Y, Watling D, Rogers NC, Stark GR. Jak2 and Stat5, but not Jak1 and Stat1, are required for prolactin-induced b-lactoglobulin transcription. Mol Endocrinol 1997;11:1180–118

  23. Walsh P, DeWeese T, Eisenberger M. Localized prostate cancer. N Engl J Med 2007;357:2696-705.

  24. Li H, Ahonen T, Alanen K, Xie J, LeBaron M, et al. Activation of signal transducer and activation of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004;64:4774-82.

  25. Dagvadorj A, Collins S, Jomain J, Abdulghani J, Karras J. Autocrine prolactin promotes prostate cancer cell growth via janus kinase-2-signal transducer and activator of transcription-5a/b signalling pathway. Endocrinology 2007;148(7):3089–101.

  26. Heinlein CA, Chang C. Androgen receptor (AR) co-regulators: an overview. Endocr Rev 2002;23:175–200.

  27. Yeung F, Li X, Ellett J, Trapmani J, et al. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. JBC 2002;75(52):40846-55.

  28. Heilein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2002;25(2):276–308.

  29. Darnell JE Jr. STATs and gene regulation. Science 1997; 12: 277 (5332): 1630-5.

  30. Li H, Zhang L, Glass A, Zellweger T. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 2005;11(16):5863-8.

  31. Lissoni P, Mandala M, Giani L, Malugani F. Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancerrelated hyperprolactinemia. Neuro Endocrinol Lett 2000;21(5):405-8.

  32. Barton B, Karras J, Murphy T, Barton A, Huang H. Signal transducer and activator of transcription activation in prostate cancer: direct STAT3 induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004;3(1):11–20.

  33. Kazansky A, Spencer D, Greenberg N. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 2003;63:8757–62.

  34. Singha B, Lancea T, Kimb K, Shawd S, Brardb L A novel indole ethyl isothiocyanate (7Me-IEITC) with antiproliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells1. Gynecol Oncol. 2008;109(2):240–9.




2020     |     www.medigraphic.com